Who is eligible for clinical trial NCT05883644?

Participants must meet protocol criteria for Advanced Hepatocellular Carcinoma. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05883644 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-04-29

Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (HCC) (NCT05883644)

A Phase IIIb Single Arm, Open-label, Multicentre Study of Durvalumab and Tremelimumab as First Line Treatment in Participants With Advanced Hepatocellular Carcinoma (SIERRA)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This study will assess the safety and efficacy of Single Tremelimumab Regular Interval Durvalumab (STRIDE) as first-line therapy in participants with advanced unresectable HCC.

Who can join: Review the eligibility criteria below.

Location: Research Site — La Jolla, California

Age range: 18 Years to 130 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (40 Sites)

Showing the first 25 of 40 sites.

Research Site — La Jolla, California
Research Site — Shreveport, Louisiana
Research Site — Detroit, Michigan
Research Site — Bobigny,
Research Site — Clichy,
Research Site — Créteil,
Research Site — Marseille,
Research Site — Rennes,
Research Site — Berlin,
Research Site — Cologne,
Research Site — Frankfurt,
Research Site — Lübeck,
Research Site — Hong Kong,
Research Site — Shatin,
Research Site — Milan,
Research Site — Naples,
Research Site — Padova,
Research Site — Pisa,
Research Site — Rozzano,
Research Site — Turin,
Research Site — Kanazawa,
Research Site — Kashiwa,
Research Site — Matsuyama,
Research Site — Musashino-shi,
Research Site — Osakasayama-shi,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Advanced Hepatocellular Carcinoma

A Study of Tegavivint (BC2059) in Patients With Advanced Hepatocellular Carcinoma — Duarte, California
A Study to Evaluate ALN-BCAT in Patients With Hepatocellular Carcinoma — Phoenix, Arizona
Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer — Atlanta, Georgia
Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial — Berkeley, California
Zanzalintinib in Second Line and Beyond for the Treatment of Advanced Liver Cancer — Chicago, Illinois

Explore by condition: All Advanced Hepatocellular Carcinoma clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗